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Abstract
Reaching out And Preventing Increases in Diabetes (RAPID) is a community-based randomized 
trial evaluating the comparative costs and effectiveness of a group-based adaption of the DPP 
lifestyle intervention developed and implemented in partnership with the YMCA.
RAPID enrolled adult primary care patients, with BMI 24 kg/m2 or higher and abnormal glucose 
metabolism (HbA1c 5.7-6.9% or fasting plasma glucose 100-125 mg/dL). 509 participants were 
enrolled and randomized to one of two groups: standard clinical advice plus free-of-charge access 
to a group-based adaption of the DPP offered by the Y, versus standard clinical advice alone. Key 
outcomes for future analysis will include differences in body weight and other cardiovascular risk 
factors over a 24-month intervention period.
At baseline, RAPID participants had a mean (SD) age of 51 ± 12.1 years, weight of 225.1 ± 56.2 
Ibs, and BMI of 36.9 ± 8.6 kg/m2. 70.7% were women, 57.2% were African American, 35.4% 
were non-Hispanic White, and 3.2% were Hispanic. Mean HbA1c was 6.05 ± 0.34%. 
Additionally, 55.4% of participants had a baseline systolic blood pressure of ≥130 mmHg, 33.1% 
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had a total blood cholesterol exceeding 200 mg/dl, and 74% reported a household income of <
$25,000.
The RAPID Study successfully randomized a large cohort of participants with a wide distribution 
of age, body weight, and race who are at high risk for developing type 2 diabetes.
Keywords
pre-diabetes; primary prevention; type 2 diabetes mellitus; overweight/obesity; lifestyle 
intervention; community research
Introduction
Over 150 million Americans are overweight or obese and at risk for weight-related 
complications such as cardiovascular disease, stroke, high blood pressure, abnormal blood 
cholesterol, type 2 diabetes, cancer, osteoarthritis, sleep apnea, depression, and chronic pain.
[1, 2] To the extent that obesity is a preventable or reversible health condition, many of 
these complications, along with their associated health implications and costs, could be 
avoided.
Past research has underscored the striking linkage between type 2 diabetes and obesity,[3] as 
well as the considerable promise of reducing the burden of diabetes through primary 
prevention. Several large clinical trials, including the U.S. Diabetes Prevention Program 
(DPP), demonstrated that resource-intensive lifestyle interventions supporting daily physical 
activity and modest weight loss can reduce the rate of developing type 2 diabetes by more 
than half.[4] Despite the promise of such interventions, even modest weight loss is 
challenging to achieve and maintain,[5] particularly among younger, more obese, minority, 
and economically disadvantaged persons.[6] Not surprisingly, the cost of offering intensive 
programs imposes barriers for routinely implementation in real-world settings.[7, 8] One 
prevailing objective of translational research in diabetes prevention is to adapt evidence-
based lifestyle interventions to be more accessible in communities and less costly to 
implement, without compromising their effectiveness.[9]
Though early research suggests that community-based adaptions of diabetes prevention 
programs can achieve meaningful weight losses at a lower overall cost, most high risk 
individuals remain unwilling or unable to pay those costs.[10] The lack of engagement in 
prevention programs not only threatens the health of individuals but also contributes to 
recent increases in healthcare expenditures.[11] As a result, there is increasing pressure for 
commercial health insurance plans and healthcare purchasers, such as employers, Medicaid, 
and Medicare, to decide whether the benefits of funding prevention programs are compelling 
enough to warrant their up-front cost and if such coverage is even feasible given the large 
numbers of persons at risk.
With the need for information to guide decisions by community organizations, health plans, 
employers, and public officials, we designed the Reaching Out to Prevent Increases in 
Diabetes (RAPID) Study, a collaborative model for diabetes prevention that links health 
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system efforts to identify high risk adults with community-based delivery of a lower cost, 
group lifestyle intervention offered by trained instructors employed by the YMCA (now 
known simply as the “Y”). This NIH-funded, community-based comparative effectiveness 
trial aims to evaluate whether a “Y Model” for translating the DPP lifestyle intervention is 
capable of reaching large numbers of high risk adults with pre-diabetes and whether that 
intervention can be cost-effective from the perspective of a health system and society over a 
2-year period. The purpose of this manuscript is to describe the design, recruitment, and 
baseline characteristics of participants in the RAPID Study.
RESEARCH DESIGN AND METHODS
Study Design and Participants
RAPID is a two-arm, parallel group, individually randomized intervention trial comparing 
standard care (including brief counseling) alone versus standard care (including brief 
counseling) plus referral to the Y for free-of-charge access to a group-based adaption of the 
DPP lifestyle intervention (known as PLAN4WARD or simply “P4W”). Study participants 
are 18 years and older with a BMI ≥24 kg/m2, no prior self-report or clinical diagnosis of 
type 2 diabetes, and at least one blood test within 6 weeks of enrollment indicating high risk 
for the development of type 2 diabetes (HbA1c level of 5.7-6.9% or plasma glucose 
concentration of 100-125 mg/dL in the fasting state).
Recruitment Flow
Nine Indianapolis-area primary care clinics (6 of which were low-income publicly 
subsidized health centers) received technical assistance from our research team to implement 
strategies to identify pre-diabetes and offer brief advice to high-risk adults about how to 
access resources to prevent type 2 diabetes. These clinics were interested in participating 
because they believed the rapid increases in type 2 diabetes among their patients were 
making it more difficult to achieve national benchmarks for diabetes care quality. Several of 
these clinics had previously worked with the research team on pilot studies in this area and 
were comfortable that the research procedures could be conducted in the clinic without 
disrupting patient care. Adult patients were informed about diabetes screening opportunities 
through a variety of strategies including mailed outreach letters, waiting room posters, and 
risk factor assessments administered by healthcare personnel during routine primary care 
visits. Patients with blood-tests indicating pre-diabetes were identified through several 
methods. First, registered dietitians who counseled high risk patients provided study 
information and referred those interested to research staff. Second, log sheets that captured 
the results of point-of-care A1c tests were used to identify patients with prior approval of 
their primary care provider. Third, data managers commissioned by the participating 
primary care practice group used electronic databases to identify patients who had 
completed one or more blood tests indicating pre-diabetes in the preceding 12 months. After 
excluding patients who had evidence of diagnosed diabetes or who were participants of 
another ongoing research study, the data manager delivered this patient list to ResNet, a 
local practice-based research network under contract with the practice group. ResNet sought 
permission from each primary care provider (PCP) to approach all of his/her patients with 
pre-diabetes. Following PCP approval, each patient was called by phone to explain the study 
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and review a short list of preliminary eligibility criteria. Each interested and potentially 
eligible patient was referred for a face-to-face visit with a Research Assistant (RA) at the 
clinic and was enrolled if repeat A1c testing confirmed the diagnosis of pre-diabetes, and if 
he/she provided written informed consent, was able to read English, was not pregnant, was 
not actively taking a medication known to alter glucose metabolism (e.g. oral steroids or 
select antipsychotic medications), and did not have a co-morbidity expected to limit lifespan 
to less than 3 years or that might contraindicate the gradual adoption of light-moderate 
physical activity (e.g. recent cardiovascular event, severe COPD, advanced arthritis, poorly 
controlled hypertension). If the patient had not recently seen a Registered Dietitian, the 
patient was offered an appointment to receive this service. The study protocol was registered 
in the National Clinical Trials Registry (NCT00656682) and approved by the Indiana 
University Purdue University Indianapolis IRB.
Metrics and Data Collection
All participants were asked at the enrollment visit to complete a limited battery of baseline 
biometric, metabolic, and survey procedures. All measurements were completed by RAs 
who worked under a business associates agreement within the Indiana University Medical 
Group and were trained by the Principal Investigator and Research Coordinator. The 
primary outcome is the between-group difference in body weight over the first 12 months. 
Body weight was measured using a commercial-grade weight scale, and height was 
measured using a wall-mounted stadiometer. Secondary outcomes include the percentage of 
participants who reach weight loss goals of 5% or more, as well as changes in blood 
pressure, total and HDL-cholesterol, and hemoglobin A1c (A1c). Blood pressures were 
assessed as the average of two values measured with an aneroid sphygmomanometer with 
participants seated and relaxed for at least 5 minutes. If the two readings differed by more 
than 10 mmHg, a third measure was taken and blood pressure was analyzed as the mean of 
the closest two values. A1c was assessed from a fingerstick capillary blood sample using a 
DCA 2000/Vantage portable bench-top analyzer.[12, 13] Non-fasting total cholesterol and 
HDL-C concentrations were measured from capillary blood using an LDX lipid analyzer.
[14, 15] Because the goal of the study was to demonstrate weight loss effectiveness of the 
adapted DPP intervention while minimizing the measurement burden on patients and 
clinicians, the RAPID Study protocol did not replicate DPP clinical trial protocols that also 
included fasting or timed glucose tolerance testing.
The RAPID Study also collected several survey-based measures that will be used in future 
analyses, including medical history information and versions of previously developed 
instruments to assess weight loss and physical activity stages-of-change [16, 17], weight loss 
and physical activity self-efficacy,[18, 19] dietary and physical activity social support,[20] 
diabetes risk perceptions,[21, 22] self-report physical activity,[23, 24] and health state utility 
(using the EuroQol 5-Dimension (EQ-5D) instrument).[25] Additional survey measures 
included an adapted version of the 17-item National Health Interview Survey (NHIS) 
Multifactor Screener short-form food frequency questionnaire,[26] with added items to 
capture changes over time in portion sizes. At follow-up visits, participants were also asked 
items from the DPP Interval History, DPP Case Report Forms, and self-report healthcare 
utilization and non-medical care cost survey.[7]
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Randomization and Blinding
Prior to beginning the study, randomization lists were generated separately for each clinic 
using SAS, version 9.2 (Cary, N.C.). Lists were created using 1:1 allocation, with blocks of 
two. The assignment for each sequential study ID was blinded in individually sealed, opaque 
envelopes kept in a locked filing cabinet accessible only to the RA in each participating 
primary care study site. Immediately after completing the baseline measures, the RA 
allocated each participant by opening the next sequentially numbered envelope, which 
included instructions specific for the treatment condition to which they were randomized. 
Although this step unblinds the participant to his/her intervention assignment, participants 
were not told they were being randomized. Instead, all participants were informed during 
enrollment that the study would provide repeat diabetes risk testing and other risk factor 
assessments, brief lifestyle counseling at the clinic, and ongoing updates about community-
based lifestyle intervention resources to help them reduce their risk for developing diabetes. 
These intervention elements were common to both study arms. As a part of the written 
informed consent, all participants agreed to allow their contact information to be made 
available to select community organizations that might contact them with information about 
additional resources. Although contact information was given to the Y for only those 
participants assigned to the P4W arm, participants remained unaware of the randomization 
process or that the types of community resource information offered to them may have 
differed from other participants. We did not disclose the step of randomization because 
unblinded studies of lifestyle interventions are subject to additional self-report biases and 
unequal loss to follow up if participants are aware they are receiving a less intensive 
treatment that they might perceive to be more beneficial (i.e. controls). Control participants 
in this study were not aware that some participants were offered a more intensive lifestyle 
intervention program at the Y. This form of “behind the scenes” randomization is common 
in pragmatic effectiveness trials where an intervention has established efficacy and no more 
than minimal risk to subjects, meaning that the step of randomizing adds no additional risks 
and simply allows the intervention (which cannot be offered to all patients) to be offered 
fairly (i.e. by coin flip), while also creating an unbiased control group who are guaranteed 
additional standard information, education, and follow-up for their condition.
Interventions
At the close of the first study visit, all participants received a study welcome packet and 
were encouraged to utilize the resources provided to assist them with goals toward diabetes 
prevention. Participants in both treatment arms (standard care; P4W) received information 
regarding community resources and self-help materials from the National Diabetes 
Education Program (NDEP)[27] to support goal-setting and the adoption of moderate 
physical activities and dietary changes to achieve modest weight loss. These community 
resources and self-help materials were provided in a written format by both study RAs and 
RDs; if the patient expressed interest, the study staff would verbally review the written 
resource materials with the patient and help the patient focus on particular resources most 
appropriate for him/her. This information was revisited at each subsequent study visit. RAs 
encouraged and assisted participants in both arms to arrange a visit with a registered 
dietitian, already employed by the practice, to obtain further assistance in developing an 
action plan for dietary changes and weight loss.
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In addition to this basic information offered to all participants, those in the P4W arm were 
also given a flier with information about how to access P4W free-of-charge through a 
nearby Y. Within 24 business hours of enrollment, a RAPID Study staff member called a 
dedicated Y-based P4W intervention coordinator and provided the name and contact 
information for any new participants assigned to the P4W arm. The Y coordinator then 
initiated a series of attempts to enroll each participant in an upcoming P4W group session, at 
a time and location that were most convenient for the participant. P4W enrollment was 
actively encouraged but not required for ongoing participation in the study.
P4W Intervention Goals and Description
The P4W intervention was based on the DPP approach and involves a structure of goal-
setting, self-monitoring, and participant-centered problem solving to achieve modest weight 
loss (5-7% reduction from baseline) through a combination of moderate physical activity 
(150 minutes per week equivalent to walking) and lower dietary fat and total calorie 
consumption.[28] In a prior study, the group-based P4W intervention was delivered by the Y 
with fidelity to the DPP model and achieved 6% mean weight loss after 6 and 12 months and 
4.8% (SE 1.4%) mean weight loss after 28 months among high risk community volunteers.
[29, 30] The Y has remained persistently committed to offering this intervention because it 
aligns with organizational values for health promotion, as well as growing interests to 
partner with healthcare, public health, and other stakeholders to preserve and improve 
population health.
P4W participants were assembled by the Y P4W coordinator into groups of 8-12 persons 
who could meet at a mutually agreeable time and location. Based on referral volumes and 
personal preference, some study participants were able to begin participating in P4W 
immediately, while others did not begin for as long as 6 months after study enrollment. 
Because the goal of this effectiveness trial was to evaluate the overall treatment effect of 
offering the DPP under “real-world” conditions, participants were not given additional 
incentives to participate or excluded from the trial for their lack of P4W participation, and 
data collection still proceeded on schedule (i.e. 6 and 12 months after baseline data 
collection) for all participants. P4W intervention locations included Y facilities and non-Y 
locations in the community, including delivery in meeting spaces within participating 
primary care clinics.
P4W involves a “core curriculum” comprised of 16 classroom-style behavioral counseling 
meetings, each lasting about 60 to 90 minutes and delivered over a period of 16 to 20 weeks.
[31] Following completion of the core curriculum visits, participants were offered monthly, 
60-minute maintenance lessons for the full duration of the trial.[30, 32] “Toolkit” incentives 
used in the DPP clinical trial to increase adherence to intervention protocols were not used 
in RAPID, but the Y did offer many participants (who were largely not Y members) limited 
guest-access to the Y, as well as other tools such as a step counter, measuring cups, spoons, 
scales, fat and calorie tracking tools, recipe guides, and other resources derived from DPP 
and previous Y programs.
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P4W Instructor Training
The P4W intervention was delivered by 31 Y personnel who underwent a 2-day training and 
recognition program.[33] Intervention locations included 6 different Y facilities associated 
with the YMCA of Greater Indianapolis. P4W instructor candidates were not required to 
have a specific academic degree or minimum level of prior training but were selected by Y 
administrators based on interest in diabetes prevention and capability to manage groups of 
wellness program participants. Instructors were typically part-time employees who had a 
mix of past training and experience with health education, coaching, and wellness 
programming. Training events included an introduction to diabetes, an overview of the DPP 
lesson structure, skill-building in the area of managing group dynamics, and a mix of role-
playing and feedback from mock lessons.
Following the training, instructors were supported through ongoing direct access to one 
another (quarterly peer-to-peer problem solving meetings), as well as to master trainers, 
project staff, and clinicians on the research team. The Y P4W coordinator completed the 
training and worked within the Y to develop procedures for direct observation of each 
instructor for quality assurance and intervention fidelity [33]. Throughout the trial, refresher 
training was offered annually and required attendance at a day-long, small group workshop, 
as well as the completion of written tests that revisited and assessed core competencies of 
the DPP intervention. All Y group instructors and the P4W coordinator were paid at rates 
typical for similar Y staff.
Statistical Analysis and Planned Analyses:
Analyses for this manuscript involved descriptive statistics summarizing the timing and 
process of recruitment approaches, as well as the baseline characteristics of the randomized 
study cohort. Future manuscripts will report on changes in body weight, other biometric, 
metabolic, and self-report outcomes, and costs. The principal analysis will focus on 
differences in body weight between randomized treatment arms following the intent to treat 
principal. However, because this is an effectiveness trial, we do not expect that all study 
participants who are offered P4W will attend the program. Thus, we will also estimate 
separately the probability of attendance when offered P4W, and the effect of P4W when it is 
received. Although such comparisons of self-selected subgroups can introduce various forms 
of selection bias we will use random treatment assignment as an instrumental variable to 
minimize that bias.[34-36]
The targeted sample size of 508 participants was expected to provide more than 80% power 
at the α=0.05 significance level to detect an absolute between-group mean difference in the 
percent weight loss at 12 months as low as 2.2% (SD 4.3%) among all randomized 
participants, as well as within the African American subgroup. This calculation assumes 
enrollment a minimum of 40% African Americans, 9 participating primary care clinics, an 
intra-cluster correlation of 2% or less for changes in weight within each clinic, and attrition 
not exceeding 15% at 12-months. These analyses will further conserve statistical power by 
using repeated measures ANOVA estimation.
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RESULTS
Recruitment Channels
Over the study's 29-month recruitment period, the 9 participating primary care clinics 
logged about 115,300 adult patient visits per year. The demographic characteristics of those 
patients varied by clinic and are presented in Table 1.
Using clinical database queries, 12,787 patients were identified during the 29-month 
recruitment period as having completed a fasting glucose test during routine clinical care 
(Table 1). Results of these tests yielded 3,064 (23.9%) patients who were in the high risk 
range (i.e. FPG 100-125 mg/dL). In parallel with RAPID Study recruitment, 6 of the 9 
participating clinic sites implemented standing order protocols and practice incentives to 
increase the completion of annual A1c testing among adults with risk factors for diabetes. 
Through A1c testing, an additional 5,217 patients completed diabetes screening, yielding 
2,137 added patients with high risk A1c test results. The success of attempts to recruit these 
high risk patients varied considerably by clinic, with more successful recruitment in clinics 
that performed more diabetes tests. In the year prior to the study, total numbers of diabetes 
tests performed varied among clinics, but testing increased most during the study in clinics 
that implemented targeted A1c testing programs. In those 6 clinics, the percentage of high 
risk patients in each clinic who underwent a screening blood test increased by 124% 
between the period 1 year before and 1 year after implementing A1c testing programs. 
Testing in the remaining 3 clinics increased only 6% over the same period. An overview of 
the success of strategic protocol changes to enhance recruitment is depicted in Figure 1.
Over the entire 29 months of recruitment, 509 participants were enrolled and randomized 
from among 3,064 patients who were identified with a high-risk glucose test and whose 
physician provided approval for recruitment. The entire recruitment flow is summarized in 
Figure 2. By assuming that the eligibility rate would have been the same among patients 
who refused screening or who could not be contacted, the 509 enrolled participants would 
represent 36% of all patients estimated as eligible in participating practices. The largest 
challenge in the recruitment flow stemmed from being unsuccessful to secure approval from 
some PCPs to approach their potentially eligible patients (unable to secure approval for 41% 
of patients with high glucose). The most common reason for this was lack of physician 
responsiveness, rather than overtly declining that patients be approached. Although our 
protocol did not enable us to collect detailed information for each reason an eligible patient 
opted out, inaccurate contact information was a common explanation for not reaching 
patients by phone. In addition, a large number of patients who were reached expressed that 
they had limited transportation or were too busy and had no time to participate in research.
Common reasons for ineligibility (n=849) among the 1,358 participants who were screened 
for the study included about 30% who reported chest pain, heart problems, breathing 
problems, arthritis or other reasons for not being able to increase their physical activity even 
gradually; 24% who reported being unable to read written English; 13% who were taking an 
anti-psychotic or oral steroid medication that could interfere with blood glucose; 11% who 
reported being diagnosed with diabetes or already taking a diabetes medication; 9% who 
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reported having a more recent blood glucose test that was normal; and 6% who had a normal 
body mass index.
Baseline Characteristics of the Randomized Cohort
The characteristics of randomized participants are shown in Table 2. The overall mean (± 
SD) age at randomization was 51.0 ± 12.1 years. More than 70% of participants were 
women and 57% were African-American. Seventy-four percent of participants reported a 
household income of <$25,000, with a mean household size of 2.7 persons. The mean 
weight (± SD) was 225.1 ± 56.2 Ibs, and mean BMI was 36.9 ± 8.6 kg/m2.
About 58% of participants reported a sibling or parent with diagnosed diabetes. Clinical 
cardiovascular risk factors were modestly elevated, reflecting the underlying high metabolic 
risk of participants but also their recruitment from primary health care settings, where blood 
pressure and antilipidemic medications could be received. Mean A1c was 6.1%. Mean 
systolic blood pressure was 132 mmHg, and was 130 mmHg or higher in 55.4% of 
participants and 140 mmHg or higher in 33.3% of participants. 61% reported taking at least 
one blood pressure medication. Mean HDL-C was 42.7 mg/dL and was below 40 mg/dL for 
approximately 45.4% of participants. Mean total cholesterol was 185.8 mg/dL and exceeded 
200 mg/dL in 33.1% of participants.
CONCLUSIONS
The Reaching out And Preventing Increases in Diabetes (RAPID) Study successfully 
recruited and randomized 509 adults with abnormal glucose metabolism, elevated BMI, and 
increased cardiovascular risk factor levels. Participants reflect the underlying population of a 
diverse mix of 9 primary care clinic recruitment sites. Successful recruitment took 
considerable time despite the underlying high prevalence of pre-diabetes in adults. A major 
challenge for recruitment was that clinical practice recommendations for targeted testing of 
adults have not been routinely implemented.[37, 38] Interestingly, prior to a push for A1c 
testing by 6 clinics, most fasting glucose tests were identified in conjunction with recent 
fasting lipid tests, suggesting that some providers recognized the related risks of 
dysglycemia and hyperlipidemia, and that the goals for treating hyperlipidemia, much like 
high blood pressure, are impacted by the co-existence of a diabetes diagnosis.[39, 40] This 
does not suggest, however, that glucose testing is being performed to identify and initiate 
interventions for pre-diabetes.
Midway through the recruitment phase of the RAPID Study, 6 clinics implemented targeted 
testing of high risk individuals using hemoglobin A1c. After that change, overall testing 
among high risk adults increased 124% over the prior year. In parallel with that increase in 
testing, recruitment into RAPID increased almost immediately from 4 participants per 
month to almost 36 participants per month (9-fold increase, depicted in Figure 1). This 
observation underscores the importance of performing glucose testing as a necessary first 
step in the management of pre-diabetes. If individuals and their PCPs remain unaware of 
diabetes risk status, they will remain ill-prepared to consider interventions that could 
improve health and prevent or delay the development of type 2 diabetes.
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It is relevant to compare the characteristics of RAPID Study participants with those of 
participants in the Diabetes Prevention Program (DPP) clinical trial. Compared with DPP, 
RAPID participants were generally of similar age (51 years in both studies) and sex (71% 
women vs. 68% in DPP), but had a higher BMI (36.9 kg/m2 vs. 34.0 kg/m2 in DPP) and 
were more likely to report African American race (57% vs. 20% in DPP) and having a 
household income below $25,000 (74% vs. about 20% in DPP).[41] Compared to DPP, 
mean A1c at baseline was also slightly higher (6.1% vs. 5.9% in DPP), SBP was higher (132 
mmHg vs. 124 mmHg in DPP), mean total cholesterol was lower (186 mg/dL vs. 203 mg/dL 
in DPP), and mean HDL-C was comparable (42.7 mg/dL vs. 43.9 mg/dL in DPP).[4, 41, 42]
Past lifestyle intervention trials such as the DPP have observed lower weight loss success 
among African Americans, women, and those who are younger, more obese, or of low 
socio-economic position.[6] Thus, the RAPID Study is uniquely positioned to evaluate the 
capacity of the Y to deliver the DPP in a way that achieves clinically meaningful weight 
losses and improved cardiovascular risk factors among adults who have proved most 
difficult to reach using structured diet and physical activity programs. If successful, our 
study will advance our understanding for how to reduce inequalities in diabetes risk and how 
to provide evidence-based interventions in a way that reaches broad segments of high risk 
adults.
Another recent trial, the Healthy Living Partnerships to Prevent Diabetes (HELP-PD) Study, 
also involved the translation and implementation of the DPP by trained community health 
workers. HELP-PD found an adjusted mean difference of 5.7% greater weight loss among 
intensive lifestyle intervention participants compared with brief education and support.[43] 
HELP-PD was a well-conducted randomized trial that reported high attendance (79%) in 
intensive intervention sessions over the first year and data collection completed by more 
than 90% of subjects at 12 months. Compared with the RAPID cohort, HELP-PD 
participants were more often men (42% vs. 29% in RAPID), non-Hispanic White (74% vs. 
35% in RAPID), older (mean age 58 years vs. 51 years in RAPID), less obese (mean BMI 
32.8 kg/m2 vs. 36.9 kg/m2 in RAPID), and likely more affluent (80% with more than a high 
school education in HELP-PD vs. only 26% reporting household income >$25,000 in 
RAPID).[44] HELP-PD recruited participants using procedures designed to maximize data 
collection and intervention participation more than to enroll a study population reflecting a 
“typical” person in the community with pre-diabetes.[45] Thus, again, RAPID is unique in 
its enrollment of a more underserved, minority, and obese study sample, and will advance 
what we can learn about both the reach and effectiveness of offering an adapted version of 
the DPP to a particularly high need population.
Because RAPID has been designed uniquely to study the effectiveness of a group-based 
adaption of the DPP among a largely underserved and vulnerable, high-risk population, we 
anticipate that we may observe lower levels of participation in lifestyle intervention lessons 
and possibly more modest, yet still meaningful changes in body weight. Importantly, we 
also expect that intervention costs will be lower and that improvements in body weight and 
other cardiometabolic risk factors will increase among those persons who attend more 
intervention visits. In addition to assessing the overall cost-effectiveness of this group 
adaption of the DPP intervention, the RAPID study is designed to provide valid estimates of 
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the intervention's effectiveness among the subgroup of high risk primary care patients who 
attend the program. It is our hope that this information will advance research as well as 
guide organizational and public policy decisions regarding how best to implement and 
sustain new activities to address the growing burden of type 2 diabetes in an equitable and 
cost-effective way.
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Figure 1. 
Relationship of Clinical and Protocol Changes to Recruitment Success Callout boxes 
describe significant protocol changes implemented to increase recruitment success; the line 
represents cumulative enrollment; increases in the slope of the line following a protocol 
change indicate more rapid recruitment success
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Figure 2. Trial Flow
Boxes and arrows indicate the flow of potentially eligible patients as deemed approachable, 
eligible, enrolled, and randomized; side arrows provide reasons for non-approach, 
ineligibility, and non-enrollment
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Table 1
Characteristics of All Adult Patients of Participating Primary Care Clinics
Characteristic Total
Total adults with visits in 2010 43,475
% Female 71.7%
Age
18-64 38,369 (88.3%)
65+ 5,106 (11.7%)
Race/Ethnicity*
African American 18,883 (43.4%)
Non-Hispanic White 18,043 (41.5%)
Hispanic 2,278 (5.2%)
Other or Unknown Race 3,930 (9.0%)
Diabetes Screening over 29 Months† 18,004
Pre-diabetes‡ identified over 29 months 5,201
*
Based on self-reported race and ethnicity data collected by clinics
†Considered screened if any random plasma glucose test was recorded with a value <100 mg/dL, or if a fasting plasma glucose or A1c test was 
performed, regardless of the result
‡
Defined before trial as fasting plasma glucose 100-125 mg/dL OR A1c test 5.7-6.9%
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Table 2
Baseline Characteristics of the Randomized Cohort
Characteristic Overall Standard Care P4W Intervention led by Y
N 509 252 257
Age (years) 51.0 (12.1) 51.2 (12.0) 50.8 (12.2)
Male 149 (29.3) 79 (31.3) 70 (27.2)
Female 360 (70.7) 173 (68.7) 187 (72.8)
African American 290 (57.0) 143 (56.8) 147 (57.2)
Non-Hispanic White 178 (35.0) 87 (34.5) 91 (35.4)
Hispanic or Latino 16 (3.1) 4 (1.6) 12 (4.7)
Other or Multi-Race 25 (4.9) 18 (7.1) 7 (2.7)
BMI (kg/m2) 36.9 (8.6) 36.53 (8.36) 37.3 (8.8)
Weight (lbs) 225.1 (55.9) 223.8 (55.9) 226.6 (56.5)
A1c 6.1 (0.3) 6.0 (0.3) 6.1 (0.3)
Systolic Blood Pressure (mmHg) 132.2 (14.6) 130.9 (13.8) 133.5 (15.2)
Diastolic Blood Pressure (mmHg) 80.3 (9.3) 80.0 (9.3) 80.5 (9.2)
Total Cholesterol (mg/dl) 185.8 (40.0) 184.5 (39.7) 187.0 (40.3)
HDL-C (mg/dl) 42.7 (14.8) 42.1 (14.2) 43.2 (15.4)
Household Income n = 422 n = 205 n = 217
    < $10,000 137 (32.5) 68 (33.2) 69 (31.8)
    $10K – $14.99K 83 (19.7) 36 (17.6) 47 (21.7)
    $15K – $24.99K 92 (21.8) 44 (21.5) 48 (22.1)
    $25K – $34.99K 39 (9.2) 17 (8.3) 22 (10.1)
    $35K – $49.99K 32 (7.6) 20 (9.8) 12 (5.5)
    $50K – $74.99K 19 (4.5) 9 (4.4) 10 (4.6)
    ≥$75,000 20 (4.7) 11 (5.4) 9 (4.2)
Family History Type 2 Diabetes n=503 n=249 n=254
290 (57.7) 143 (57.4) 147 (57.9)
Data are means ± SD or n (%) unless otherwise stated. Percentages may not add up to 100 because of rounding.
*Eligibility criteria: age ≥18 years, A1c 5.7-6.9% OR fasting plasma glucose 5.6–6.9 mmol/l (100-125 mg/dl), BMI ≥24 kg/m2, and systolic/
diastolic blood pressure <180/105 mmHg.
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